Overview

Useful For
Identification of heredity elevation or deficiency of plasminogen activator inhibitor type 1

Determination of risk for veno-occlusive disease associated with bone marrow transplantation

Differential diagnosis of impaired fibrinolysis

Prognostic marker of occurrence or recurrence of thrombosis

Special Instructions
- Coagulation Guidelines for Specimen Handling and Processing

Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)

NY State Available
Yes

Specimen

Specimen Type
Plasma Na Cit

Specimen Required
See Coagulation Guidelines for Specimen Handling and Processing in Special Instructions.

Specimen Type: Platelet-poor plasma

Collection Container/Tube: Light-blue top (citrate)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:
1. Spin down, remove plasma, and spin plasma again.
2. Freeze specimen immediately at < or =-40 degrees C, if possible.

Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.

Forms
Test Definition: PAI1
PAI-1 Ag, P

If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.

Specimen Minimum Volume
0.3 mL

Reject Due To

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross hemolysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gross lipemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gross icterus</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Specimen Stability Information

Clinical and Interpretive

Clinical Information

Plasminogen activator inhibitor type 1 (PAI-1) antigen is a single-chain glycoprotein (MW 50,000) produced by endothelial cells and hepatocytes and is also present in alpha granules of platelets. PAI-1 is a serine protein inhibitor that is secreted in response to inflammatory reactions. Platelet alpha granules contain large amounts of PAI-1, which is released during vascular injury and assists in fibrin clot stability. PAI-1 is synthesized in the active form but has marked functional instability and a functional half-life of about 2 hours in vivo. Circulating PAI-1 is bound to vitronectin, which protects the inhibitor from inactivation and may assist in targeting the inhibitor to sites of vascular injury. At least 4 different conformations of PAI-1 have been described: 1) the active form that reacts with plasminogen activator; 2) a latent form that is nonreactive; 3) a substrate form that can be cleaved by plasminogen activators but is noninhibitory; and 4) the inert form of PAI-1 generated by the cleavage of the reactive site.

PAI-1 is the main inhibitor of tissue-type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) and, as such, plays an important role in the regulation of fibrinolysis. Elevated levels of PAI-1 result in deficient plasminogen activation and are associated with a predisposition to thrombosis, including veno-occlusive disease (VOD) after bone marrow transplantation (BMT).

Primary injury to the hepatic sinusoidal endothelium and hepatocytes induced by high-dose chemoradiotherapy is believed to be the key event in the pathogenesis of VOD. The clinical diagnosis of VOD is complex because the clinical signs and symptoms can occur as a result of other processes that can complicate the posttransplant period such as sepsis, graft-versus-host disease (GVHD), cyclosporine toxicity, other medications, hemolysis, or parenteral nutrition. Liver biopsy, although safer since the widespread introduction of transjugular procedures, remains hazardous in this thrombocytopenic population. A sensitive and specific assay would be invaluable in guiding management and avoiding potentially hazardous invasive diagnostic procedures. Along these lines several investigators have studied various markers of hypercoagulability for possible pathogenic and predictive relevance. Aside from serum bilirubin level, no laboratory marker has been standardized as a diagnostic marker of VOD and the severity of VOD remains retrospectively defined. Lee et al analyzed 115 patients after allogenic BMT in an attempt to identify diagnostic and severity markers of VOD. Of the 115 patients, 50 developed VOD.(1) Multiple logistic regression models were constructed that included recognized relevant clinical and hemostatic variables. Of the hemostatic variables, only PAI-1 antigen was identified as an independent marker for the occurrence of VOD. This confirmed findings of an earlier, smaller study, that PAI-1 is a powerful diagnostic marker of VOD during the early
period post-BMT, and can distinguish VOD from other causes of hyperbilirubinemia post-BMT such as GVHD and drug toxicity. Furthermore, PAI-1 antigen and bilirubin were independent variables for predicting severe VOD.

Familial thrombosis has been associated with inherited elevation of plasma PAI-1 activity. Increased levels of PAI-1 have also been reported in a number of conditions including malignancy, liver disease, the postoperative period, septic shock, the second and third trimesters of pregnancy, obesity, and coronary heart disease.

Low plasma levels of the active form of PAI-1 have been associated with abnormal, clinically significant bleeding. Complete deficiency of PAI-1, either congenital or acquired, is associated with bleeding manifestations that include hemorrhathoses, hematomas, menorrhagia, easy bruising, and postoperative hemorrhage.

**Reference Values**

3-72 ng/mL

**Interpretation**

Increased levels of plasminogen activator inhibitor type 1 (PAI-1) are associated with a predisposition to thrombosis.

Decreased or absent levels of detectable functional PAI-1 will result in a life-long bleeding diathesis.

**Cautions**

The plasminogen activator inhibitor type 1 (PAI-1) level shows a diurnal variation with the highest levels occurring in the morning.

The PAI-1 level increases during pregnancy and decreases rapidly after delivery.

The extremely rare presence of antimouse antibodies in certain patients may lead to anomalous results.

Inappropriate specimen collection and processing may lead to platelet activation and release of platelet PAI-1. Consequently, care must be taken to remove all platelets and minimize platelet activation during specimen collection and processing.

**Clinical Reference**


7. Fay WP, Shapiro AD, Shih JL, et al: Brief report: complete deficiency of plasminogen-activator inhibitor Type 1 due
Performance

Method Description
Testing is performed on the Biomek FXP liquid handling system using the Diagnostica Stago, Inc. Asserachrom PAI-1 kit. The method used is an enzyme-linked immunosorbent assay (ELISA). Microtiter plate wells are coated with mouse monoclonal antihuman PAI-1 antibody, which captures the PAI-1 in the sample. Next, a second antibody (mouse monoclonal antihuman PAI-1) coupled with peroxidase binds to another antigenic site distant from the first antibody, forming the "sandwich". The bound enzyme peroxidase is then visualized based on its ability to produce a color reaction when exposed to ortho-phenylenediamine and hydrogen peroxide. The reaction is stopped by the addition of a strong acid (1N HCl). The intensity of the color produced is directly proportional to the PAI-1 concentration in the plasma sample. (Declerck PJ, Alessi MC, Verstreken M, et al: Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988;71[1]:220-225)

PDF Report
No

Day(s) and Time(s) Test Performed
Wednesday

Analytic Time
7 days

Maximum Laboratory Time
12 days

Specimen Retention Time
7 days

Performing Laboratory Location
Rochester

Fees and Codes
Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
85415

LOINC® Information
### Test Definition: PAI1

**PAI-1 Ag, P**

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAI1</td>
<td>PAI-1 Ag, P</td>
<td>22758-7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>86083</td>
<td>PAI-1 Ag, P</td>
<td>22758-7</td>
</tr>
</tbody>
</table>